17 research outputs found
<i>Salmonella</i> strains isolated from humans and animals in the same compound and their Sequence Types profiles.
<p><i>Salmonella</i> strains isolated from humans and animals in the same compound and their Sequence Types profiles.</p
Map of the Gambia showing the locations where Non-Typhoidal <i>Salmonella</i> were recovered in humans from the surveillance area in The Gambia.
<p>Map of the Gambia showing the locations where Non-Typhoidal <i>Salmonella</i> were recovered in humans from the surveillance area in The Gambia.</p
Clinical symptoms present in 14 Gambian children with Non-Typhoidal <i>Salmonella</i> infections.
<p>Clinical symptoms present in 14 Gambian children with Non-Typhoidal <i>Salmonella</i> infections.</p
Dendrogram based on the concatenated sequences of the seven alleles from the 35 NTS.
<p>The scale bar represents percentage (%) of similarity.</p
Categorisation of the patient population by diagnostic criteria.
<p>Categorisation of the patient population by diagnostic criteria.</p
Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018
Background: Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir.Aim: To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2).Design and setting: Exploratory analysis of data from an open-label, pragmatic, randomised controlled trial during three influenza seasons, from 2016 to 2018, in primary care research networks, in 15 European countries.Method: Patients aged ≥1 year presenting to primary care with influenza-like illness (ILI), and who tested positive for coronavirus (not including SARS-CoV-2), were randomised to usual care or usual care plus oseltamivir. The primary outcome was time to recovery defined as a return to usual activities, with minor or absent fever, headache, and muscle ache.Results: Coronaviruses (CoV-229E, CoV-OC43, CoV-KU1 and CoV-NL63) were identified in 308 (9%) out of 3266 randomised participants in the trial; 153 of these were allocated to usual care and 155 to usual care plus oseltamivir; the primary outcome was ascertained in 136 and 147 participants, respectively. The median time to recovery was shorter in patients randomised to oseltamivir: 4 days (interquartile range [IQR] 3-6) versus 5 days (IQR 3-8; hazard ratio 1.31; 95% confidence interval = 1.03 to 1.66; P = 0.026).Conclusion: Primary care patients with ILI testing positive for coronavirus (not including SARS-CoV-2) recovered sooner when oseltamivir was added to usual care compared with usual care alone. This may be of relevance to the primary care management of COVID-19.</div
Reads of viruses after antibody capture.
a<p>Only enriched sequences with the potency to be viral are shown, so no known bacterial, human, fungal, etc. or other sequences are included.</p>b<p>Control, non pathogenic viruses.</p
Collection of serum in month(s) after infection.
<p>Collection of serum in month(s) after infection.</p
Decrease in ribosomal RNA after antibody capture.
<p>Ribosomal RNA was measured in the input material and the captured material. On the Y-axis the Ct value of the real time PCR on the cDNA is shown.</p
Reads of viruses after antibody capture.
a<p>The enrichment index is calculated by dividing the percentage of virus reads in the captured material by the number of virus reads in the input material.</p>b<p>Control, non pathogenic viruses.</p